Investigation of the usefulness of a screening test for pancreatic cancer based on highly sensitive detection of gene mutations in duodenal juice collected using synthetic human secretin and a specially-made catheter following conventional gastrointestinal endoscopy in high-risk individuals

Yachida Shinichi0 sites120 target enrollmentJanuary 22, 2021

Overview

No summary available.

Registry

who.int

Start Date

January 22, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Yachida Shinichi

•1\) Patient\-provided informed consent and over 20 years old
•2\) Patients in high\-risk groups for pancreatic cancer (Onomichi City Cohort, Matsue City Cohort, Kokugan Cohort, Osaka National Cancer Center Cohort, Wakayama Medical University Cohort, Aichi Cancer Center Cohort) on whom EUS,EUS\-FNA, or ERCP will be performed
•3\) Persons who have given their written consent to participate in this research

•1\) Patients with hypersensitivity to secretin or other ingredients (excipients: cysteine hydrochloride and mannitol)
•2\) Patients in remission from acute pancreatitis or acute exacerbations of chronic pancreatitis within 2 weeks of the start of administration of the study drug
•3\) Patients who don't discontinue anticholinergic drugs at least 5 half\-lives prior to the start of administration of the study drug
•4\) Pregnant or lactating women
•5\) Patients who received other research drugs or investigational drugs within 3 months of the start of administration of the study drug
•6\) Patients who are hard to observe a duodenal papilla with an endoscope
•7\) Patients whom the doctor in charge judges inappropriate